Global Vaccine Contract Manufacturing Market to Reach $4.3 Billion by 2027

10 Mar 2021
www.globenewswire.com
VaccineCollaborate
New York, March 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaccine Contract Manufacturing Industry" - In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: - Global Vaccine Contract Manufacturing Market to Reach $4.3 Billion by 2027 - Amid the COVID-19 crisis, the global market for Vaccine Contract Manufacturing estimated at US$2.5 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 8% over the analysis period 2020-2027. Attenuated, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$1.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Inactivated segment is readjusted to a revised 8.2% CAGR for the next 7-year period. - The U.S. Market is Estimated at $672.6 Million, While China is Forecast to Grow at 12.1% CAGR - The Vaccine Contract Manufacturing market in the U.S. is estimated at US$672.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$960.8 Million by the year 2027 trailing a CAGR of 12% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR. - Subunit-based Segment to Record 8.4% CAGR - In the global Subunit-based segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$280.9 Million in the year 2020 will reach a projected size of US$475.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$590.6 Million by the year 2027, while Latin America will expand at a 10% CAGR through the analysis period. Select Competitors (Total 34 Featured) - Ajinomoto Althea, Inc. Albany Molecular Research, Inc. Catalent, Inc. Cobra Bio Cytovance Biologics Fujifilm Diosynth Biotechnologies U.S.A., Inc. Icon plc IDT Biologika KBI Biopharma Lonza Read the full report: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Vaccine Contract Manufacturing Competitor Market Share Scenario Worldwide (in %): 2020E Global Competitor Market Shares by Segment 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Vaccine Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Subunit-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Subunit-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Toxoid-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Toxoid-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for DNA-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for DNA-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Veterinary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Veterinary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Market Facts & Figures Market Analytics Table 25: USA Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 28: USA Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 29: USA Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: USA 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 CANADA Table 31: Canada Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 34: Canada Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: Canada Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: Canada 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 JAPAN Table 37: Japan Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: Japan Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: Japan 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 40: Japan Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: Japan Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: Japan 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 CHINA Table 43: China Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: China Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: China 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 46: China Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: China Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: China 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures Market Analytics Table 49: Europe Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Vaccine Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: Europe 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 55: Europe Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: Europe 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 FRANCE Table 58: France Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: France Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: France 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 61: France Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: France Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: France 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 GERMANY Table 64: Germany Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Germany Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Germany 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 67: Germany Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Germany Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Germany 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 ITALY Table 70: Italy Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: Italy Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: Italy 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 73: Italy Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: Italy Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: Italy 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 76: UK Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: UK Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: UK 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 79: UK Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: UK Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: UK 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 SPAIN Table 82: Spain Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Spain Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Spain 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 85: Spain Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Spain Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Spain 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 RUSSIA Table 88: Russia Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Russia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Russia 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 91: Russia Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Russia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Russia 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 REST OF EUROPE Table 94: Rest of Europe Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 95: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Rest of Europe 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 97: Rest of Europe Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Rest of Europe Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Rest of Europe 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 100: Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 103: Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 106: Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 AUSTRALIA Table 109: Australia Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 110: Australia Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: Australia 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 112: Australia Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: Australia Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: Australia 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 INDIA Table 115: India Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 116: India Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 117: India 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 118: India Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 119: India Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 120: India 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 SOUTH KOREA Table 121: South Korea Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 122: South Korea Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 123: South Korea 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 124: South Korea Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 125: South Korea Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 126: South Korea 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 REST OF ASIA-PACIFIC Table 127: Rest of Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 128: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Vaccine Type - Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 129: Rest of Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Vaccine Type - Percentage Breakdown of Value Sales for Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based for the Years 2012, 2020 & 2027 Table 130: Rest of Asia-Pacific Current & Future Analysis for Vaccine Contract Manufacturing by Application - Human and Veterinary - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 131: Rest of Asia-Pacific Historic Review for Vaccine Contract Manufacturing by Application - Human and Veterinary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 132: Rest of Asia-Pacific 15-Year Perspective for Vaccine Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Human and Veterinary for the Years 2012, 2020 & 2027 LATIN AMERICA Table 133: Latin America Current & Future Analysis for Vaccine Please contact our Customer Support Center to get the complete Table of Contents Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.